- Latest available (Revised)
- Original (As made)
There are currently no known outstanding effects for the The Human Medicines Regulations 2012, Paragraph 27.
Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.
27.—(1) Electronic PSURs must be submitted in the following format—
(a)Part I: title page including signature;
(b)Part II: executive summary; and
(c)Part III: table of contents which contains—
(i)introduction,
(ii)worldwide marketing authorisation status,
(iii)actions taken in the reporting interval for safety reasons,
(iv)changes to reference safety information,
(v)estimated exposure and use patterns—
(aa)cumulative subject exposure in clinical trials,
(bb)cumulative and interval patient exposure from marketing experience,
(vi)data in summary tabulations—
(aa)reference information,
(bb)cumulative summary tabulations of serious adverse events in clinical trials,
(cc)cumulative and interval summary tabulations from post-marketing data sources,
(vii)summaries of significant findings from clinical trials during the reporting interval—
(aa)completed clinical trials,
(bb)ongoing clinical trials,
(cc)long-term follow-up,
(dd)other therapeutic use of medicinal product,
(ee)new safety data related to fixed combination therapies,
(viii)findings from non-interventional studies,
(ix)information from other clinical trials and sources,
(x)non-clinical data,
(xi)literature,
(xii)other periodic reports,
(xiii)lack of efficacy in controlled clinical trials,
(xiv)late-breaking information,
(xv)overview on signals: new, ongoing or closed,
(xvi)signal and risk evaluation—
(aa)summaries of safety concerns,
(bb)signal evaluation,
(cc)evaluation of risks and new information,
(dd)characterisation of risks, and
(ee)effectiveness of risk minimisation (if applicable),
(xvii)benefit evaluation—
(aa)important baseline efficacy and effectiveness information,
(bb)newly identified information on efficacy and effectiveness, and
(cc)characterisation of benefits,
(xviii)integrated benefit-risk analysis for authorised indications—
(aa)benefit-risk context: medical need and important alternatives, and
(bb)benefit-risk analysis evaluation,
(xix)conclusions and actions, and
(xx)appendices to the PSUR.
(2) In this paragraph, “signal evaluation” means the process of further evaluating a validated signal taking into account all available evidence, to determine whether there are new risks causally associated with the active substance or medicinal product, or whether known risks have changed, and that process—
(a)may include non-clinical and clinical data; and
(b)must be as comprehensive as possible regarding the sources of information used for that process.]
Textual Amendments
F1Sch. 12A inserted (31.12.2020) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), reg. 1, Sch. 6 (as amended by S.I. 2019/1385, reg. 1, Sch. 1 para. 9 and S.I. 2020/1488, reg. 1, Sch. 2 para. 192); 2020 c. 1, Sch. 5 para. 1(1)
The Whole Instrument you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
The Whole Instrument you have selected contains over 200 provisions and might take some time to download.
Would you like to continue?
The Whole Instrument you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
The Whole Instrument without Schedules you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
The Schedules you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.
Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Explanatory Memorandum sets out a brief statement of the purpose of a Statutory Instrument and provides information about its policy objective and policy implications. They aim to make the Statutory Instrument accessible to readers who are not legally qualified and accompany any Statutory Instrument or Draft Statutory Instrument laid before Parliament from June 2004 onwards.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
Impact Assessments generally accompany all UK Government interventions of a regulatory nature that affect the private sector, civil society organisations and public services. They apply regardless of whether the regulation originates from a domestic or international source and can accompany primary (Acts etc) and secondary legislation (SIs). An Impact Assessment allows those with an interest in the policy area to understand:
This timeline shows the different points in time where a change occurred. The dates will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. The first date in the timeline will usually be the earliest date when the provision came into force. In some cases the first date is 01/02/1991 (or for Northern Ireland legislation 01/01/2006). This date is our basedate. No versions before this date are available. For further information see the Editorial Practice Guide and Glossary under Help.
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: